March 27, 2020

President Donald J. Trump The White House 1600 Pennsylvania Avenue NW Washington, DC 20500

Dear Mr. President:

As our nation battles the unprecedented challenge of the COVID-19 pandemic, your leadership in responding to the severity of the crisis is greatly appreciated. Stemming the spread of the coronavirus while providing critical support to the U.S. economy is the nation's highest priority. We appreciate your Administration's coordinated efforts, as well as the bipartisan leadership in Congress, to help ensure that our public health emergency and economic challenges are met. We, as patients, consumers, taxpayers, health care providers, payers, and members of the pharmaceutical and medical device pipeline, are ready to work with you and your Administration to ensure that America's patients and our health care system receive the treatments they need throughout this public health crisis.

As you take action through Executive Order or in coordination with Congress, it is critical that those policies do not restrict access to — or destabilize the supply chain for — currently available pharmaceuticals or medical devices. At this time, while supply chains for a broad range of U.S. industries are stressed due to the global COVID-19 crisis and a number of factors related to the crisis have already raised concerns about shortages, it is important that we do not take any measures that could undermine the complex arrangements between firms that allow for efficient delivery of medicines to patients.

Today, patients in the United States and around the world depend on the use of global supply chains that facilitate ongoing access to needed medicines. These supply chains have been built over decades and include appropriate safeguards to ensure safety and efficacy of products. Keeping that supply chain strong is even more critical as we fight a global pandemic. That's why the biopharmaceutical industry has been working together with the U.S. Food and Drug Administration to take significant steps to ensure continuity in our medicine supply. Proposals to drive all manufacturing to the United States not only overestimate the potential feasibility and underestimate the time and effort it would take to make such changes, but also misunderstand that a diverse pharmaceutical supply chain is precisely what enables the industry to respond quickly and make adjustments in its supply chain sourcing during natural emergencies and global public health crises.

We are committed to working with you to combat the COVID-19 crisis, ensure continued access to pharmaceuticals and devices for America's patients and providers caring for them, and develop incentives that result in renewing the domestic manufacturing base for health care products in the United States. Thank you for considering our views and for your ongoing leadership during this unprecedented crisis.

Sincerely,

60 Plus Association

Academy of Managed Care Pharmacy

Advocacy & Awareness for Immune Disorders Association

The AIDS Institute

Allergy & Asthma Network

Alliance for Aging Research

American Autoimmune Related Diseases Association

American Behcet's Disease Association

American Cancer Society Cancer Action Network

American Consumer Institute

American Diabetes Association

American Kidney Fund

Arthritis Foundation

ASPIRE: Alliance to Solve PANS & Immune-Related Encephalopathies

Association for Accessible Medicines

Asthma and Allergy Foundation of America

Autoimmune Encephalitis Alliance, Inc.

Beyond Celiac

Black Women's Health Imperative

Center for Freedom and Prosperity

Conquer Myasthenia Gravis

Consumer Action

Consumer Healthcare Products Association

Council for Citizens Against Government Waste

Cutaneous Lymphoma Foundation

Dysautonomia International

Endocrine Society

FreedomWorks

Frontiers of Freedom

GO2 Foundation for Lung Cancer

Global Healthy Living Foundation

Healthcare Distribution Alliance

HealthHIV

HIV + Hepatitis Policy Institute

Immune Deficiency Foundation

Innovative Defense Foundation

International Foundation for Autoimmune & Autoinflammatory Arthritis

International Myeloma Foundation

International Pemphigus Pemphigoid Foundation

LUNGevity Foundation

Lupus and Allied Diseases Association, Inc.

Lupus Foundation of America

Marti Nelson Cancer Foundation

Mended Hearts & Mended Little Hearts

Mental Health America

Myasthenia Gravis Foundation of America

The Myositis Association

National Alliance on Mental Illness

National Alopecia Areata Foundation

National Consumers League

National Eczema Association

National Health Council

National Multiple Sclerosis Society

National Psoriasis Foundation

National Taxpayers Union

Osteogenesis Imperfecta Foundation

Partnership to Fight Chronic Disease

PhRMA

Prevent Cancer Foundation

R Street Institute

Sjögren's Foundation

Spina Bifida Association

Susan G. Komen

Taxpayers Protection Alliance

USP

U.S. Pain Foundation

Us TOO International

Vitiligo Support International